Midazolam + Dexmedetomidine
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Critical Illness
Conditions
Critical Illness
Trial Timeline
Aug 1, 2008 → Oct 1, 2012
NCT ID
NCT00744380About Midazolam + Dexmedetomidine
Midazolam + Dexmedetomidine is a pre-clinical stage product being developed by Pfizer for Critical Illness. The current trial status is completed. This product is registered under clinical trial identifier NCT00744380. Target conditions include Critical Illness.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00744380 | Pre-clinical | Completed |
Competing Products
13 competing products in Critical Illness
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Daptomycin | Merck | Approved | 85 |
| Ceftolozane/Tazobactam - Multiple Doses + Ceftolozane/Tazobactam - Single Dose | Merck | Phase 1 | 33 |
| Evolocumab 140mg/mL Injector 1milliliter (mL) Pen x 3 for a monthly dose of 420 mg for 12 months. | Amgen | Approved | 84 |
| intensive insulin therapy to maintain normoglycemia | Novo Nordisk | Phase 2 | 51 |
| Apixaban + ASA + Clopidogrel 75mg | Pfizer | Phase 3 | 76 |
| Colchicine (Colcrys®) + placebo + allopurinol | Regeneron Pharmaceuticals | Approved | 84 |
| Rilonacept 80 mg + Rilonacept 160 mg | Regeneron Pharmaceuticals | Phase 3 | 76 |
| treprostinil dienthanolmine sustained release + Placebo | United Therapeutics | Phase 2 | 49 |
| Remodulin® (treprostinil sodium) Injection | United Therapeutics | Phase 3 | 74 |
| Olimel (5.7%E / N9E) | Baxter | Phase 3 | 74 |
| Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E | Baxter | Approved | 82 |
| RJX + Placebo | ICON plc. | Phase 1 | 30 |
| Ixmyelocel-T | Vericel | Phase 3 | 72 |